MX2022004637A - Antigenos de la vacuna contra la enfermedad de chagas con estabilidad mejorada y agregacion disminuida. - Google Patents
Antigenos de la vacuna contra la enfermedad de chagas con estabilidad mejorada y agregacion disminuida.Info
- Publication number
- MX2022004637A MX2022004637A MX2022004637A MX2022004637A MX2022004637A MX 2022004637 A MX2022004637 A MX 2022004637A MX 2022004637 A MX2022004637 A MX 2022004637A MX 2022004637 A MX2022004637 A MX 2022004637A MX 2022004637 A MX2022004637 A MX 2022004637A
- Authority
- MX
- Mexico
- Prior art keywords
- chagas disease
- protein
- improved stability
- tsa
- vaccine antigens
- Prior art date
Links
- 241000223109 Trypanosoma cruzi Species 0.000 title abstract 4
- 206010001935 American trypanosomiasis Diseases 0.000 title abstract 2
- 208000024699 Chagas disease Diseases 0.000 title abstract 2
- 230000003247 decreasing effect Effects 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title 1
- 238000004220 aggregation Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010037277 thymic shared antigen-1 Proteins 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan composiciones y métodos para la prevención y tratamiento de la enfermedad de Chagas y sus síntomas crónicos y agudos. Las composiciones comprenden proteínas recombinantes basadas en un fragmento terminal amino de la proteína TSA-1 del Trypanosoma cruzi. En el fragmento, uno o más residuos Cys son mutados para prevenir la formación de enlaces disulfuro y para mejorar la solubilidad. Las proteínas recombinantes también incluyen un fragmento terminal carboxilo de la proteína TSA-1 del Trypanosoma cruzi para proporcionar estabilidad y solubilidad adicionales. La proteína recombinante resultante permanece soluble bajo un almacenamiento prolongado a bajas temperaturas y provoca una respuesta inmune robusta cuando es administrada, incluyendo la disminución del número de células inflamatorias en el tejido del corazón de los sujetos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916391P | 2019-10-17 | 2019-10-17 | |
| PCT/US2020/055504 WO2021076570A2 (en) | 2019-10-17 | 2020-10-14 | Chagas disease vaccine antigens with improved stability and decreased aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004637A true MX2022004637A (es) | 2023-02-22 |
Family
ID=75538068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004637A MX2022004637A (es) | 2019-10-17 | 2020-10-14 | Antigenos de la vacuna contra la enfermedad de chagas con estabilidad mejorada y agregacion disminuida. |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20240108707A1 (es) |
| MX (1) | MX2022004637A (es) |
| WO (1) | WO2021076570A2 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006151813A (ja) * | 2003-01-31 | 2006-06-15 | Sangaku Renkei Kiko Kyushu:Kk | 細胞内寄生病原体に対する遺伝子ワクチン |
| WO2017160849A1 (en) * | 2016-03-14 | 2017-09-21 | Baylor College Of Medicine | Tc24-c4, a chagas disease vaccine antigen with improved stability and decreased aggregation |
-
2020
- 2020-10-14 US US17/769,113 patent/US20240108707A1/en active Pending
- 2020-10-14 MX MX2022004637A patent/MX2022004637A/es unknown
- 2020-10-14 WO PCT/US2020/055504 patent/WO2021076570A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021076570A3 (en) | 2021-05-27 |
| US20240108707A1 (en) | 2024-04-04 |
| WO2021076570A2 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dandekar et al. | Th17 cells, HIV and the gut mucosal barrier | |
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| ES2897635T3 (es) | Métodos y composiciones para modular el sistema inmunológico con la arginasa I | |
| MX2020010465A (es) | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| MX2009008843A (es) | Peptidomimeticos fijados a un patron. | |
| EP3889185A3 (en) | Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage | |
| JP2019501920A5 (es) | ||
| WO2015190378A1 (ja) | 安定なアダリムマブ水性製剤 | |
| RU2010113994A (ru) | Применение панкреатического полипептида человека в качестве терапевтического средства | |
| MX2022004637A (es) | Antigenos de la vacuna contra la enfermedad de chagas con estabilidad mejorada y agregacion disminuida. | |
| WO2020106876A3 (en) | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease | |
| WO2016122806A8 (en) | Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life | |
| JP2016534062A5 (es) | ||
| WO2011090973A3 (en) | Immunotherapy compositions and methods of treatment | |
| Khandelwal et al. | Plasma exchanges and immunosuppression for anti-complement factor H associated hemolytic uremic syndrome | |
| RU2018118836A (ru) | Препарат фактора свёртывания крови viii | |
| Cheung et al. | Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical α1-adrenoceptor antagonist | |
| RU2021108562A (ru) | Фармацевтические композиции и способы, связанные с ушными терапевтическими агентами | |
| Koutsoviti et al. | JOURN AL OF R H E U M | |
| Orsić | THE MEDITERRANEAN ORIENTATION OF SERBIAN LITERATURE | |
| Giustozzi et al. | Impact of sex and risk factors for venous thromboembolism on the clinical course of first acute venous thromboembolism. Insights from the PREFER in VTE | |
| 徐希奇 | Comparison of clinical characteristics and survival on patients with idiopathic pulmonary arterial hypertension and familial pulmonary arterial hypertension during conventional therapy era and targeted therapy era | |
| WO2020012243A3 (en) | Pharmaceutical composition containing a peptide | |
| Dimitrova et al. | New low molecular collagen-a number one treatment in wrinkle care and anti-aging processes | |
| CARLI | Adherence to Influenza and Meningococcal vaccination in patients with Systemic Lupus Erythematosus referred to the AOU in Pisa and to the Guy’s and St Thomas’ NHS Foundation Trust in London |